Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Aspirin use and cognitive function in the elderly

T Stürmer¹, R J Glynn, T S Field

¹Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

American Journal of Epidemiology

|April 1, 1996

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A prospective study of blood pressure and risk of cataract in men.

Annals of epidemiology·2001

Same author

G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism.

Journal of the American College of Cardiology·2001

Same author

Relations of body fat distribution and height with cataract in men.

The American journal of clinical nutrition·2000

Same author

Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in Men.

Hypertension (Dallas, Tex. : 1979)·2000

Same author

An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease.

Archives of internal medicine·2000

Same author

Clinical and research challenges in risk factors for cardiovascular diseases.

European heart journal·2000

Same journal

A decision-theoretic framework for uncertainty quantification in epidemiological modelling.

American journal of epidemiology·2026

Same journal

U.S. cardiovascular mortality before and during COVID-19: CDC WONDER vs GBD comparison.

American journal of epidemiology·2026

Same journal

Design and procedures for the greenness, cognitive performance and vascular outcomes in the northern Manhattan study (NOMAS-greenness).

American journal of epidemiology·2026

Same journal

Correction to: Home dampness and molds and occurrence of respiratory tract infections in the first 27 years of life: the Espoo Cohort Study.

American journal of epidemiology·2026

Same journal

A SIMPLE AND POWERFUL TEST OF VACCINE WANING.

American journal of epidemiology·2026

Same journal

Association Between maternal body mass index, offspring growth and pubertal timing: results from a longitudinal birth cohort study.

American journal of epidemiology·2026

See all related articles

Aspirin use did not show a substantial effect on cognitive decline in the elderly. However, the study suggests a potential modest benefit, particularly with intermittent aspirin use, warranting further investigation.

Area of Science:

Gerontology
Neuroscience
Public Health

Background:

Cognitive decline in older adults is a significant public health issue.
Aspirin's potential role in mitigating cognitive decline, particularly multi-infarct dementia, is under-researched.

Purpose of the Study:

To investigate the association between aspirin use and cognitive function decline in community-dwelling elderly individuals.
To explore potential benefits of aspirin, including intermittent use, on cognitive health in aging populations.

Main Methods:

Population-based cohort study (East Boston Senior Health Project) with 3,809 participants aged 65+.
Cognitive function assessed using the Short Portable Mental Status Questionnaire; medication use, including aspirin, recorded.
Multiple logistic regression and estimating equation approach used to analyze cognitive decline and aspirin use, adjusting for repeated measures.

Related Experiment Videos

Main Results:

Aspirin users had an odds ratio of 0.97 (95% CI 0.82-1.15) for cognitive decline.
Low-frequency (less than daily) aspirin use showed an odds ratio of 0.87 (95% CI 0.69-1.09).
No substantial effect was observed, but results are compatible with a modest benefit from intermittent aspirin use.

Conclusions:

Current data do not demonstrate a significant protective effect of aspirin against cognitive decline in the elderly.
A potential modest benefit, especially with intermittent aspirin use, cannot be ruled out.
Randomized controlled trials are necessary to definitively ascertain aspirin's impact on cognitive function decline.